Walder Wyss with CRISPR Therapeutics on USD 600 m notes issuance

Walder Wyss advised Nasdaq-listed CRISPR Therapeutics, as the Switzerland-based biopharmaceutical company issued a USD 600 million aggregate principal amount of convertible senior notes.

The convertible senior notes were offered in a private offering to qualified institutional buyers. The convertible senior notes carry a semiannual effective coupon of 1.7308% and will mature on 1 March 2031, unless earlier converted, redeemed or repurchased.

The Walder Wyss team

Partners Alex Nikitine (corporate / M&A, capital markets) and Iliana Djagova (corporate / M&A, capital markets) led the Walder Wyss team on the matter, working alongside managing associate Dimitrios Berger (corporate / M&A, capital markets) and associate Kevin Caratsch (corporate / M&A, capital markets) as well as partner Maurus Winzap (tax) and managing associate Vangelis Kalaitzidakis (tax).